Trial site
Studienzentrum Dr. Bischof GmbH
Boeblingen, 71034, GermanyNot linked to an institution yet
- 9running trials
- 9closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 24 trials
- Phase 2/31 trial
- Status
- Completed9 trials
- Active, not recruiting5 trials
- Not yet recruiting2 trials
- Recruiting2 trials
- Lead sponsor
- Hoffmann-La Roche2 trials
- Sanofi2 trials
- Zenas BioPharma (USA), LLC2 trials
- AbbVie1 trial
- Boehringer Ingelheim International GmbH1 trial
- and 10 more
Running trials
Active, not recruiting
A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and safety of two dexamfetamine sulfate formulations in adults with ADHD - DEXINA -
2022-502903-31-00· Phase 3· Medice Arzneimittel Puetter GmbH & Co. KG· Source
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472· Phase 2/3· Exciva GmbH· Source
Recruiting
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· Phase 3· Sanofi· Source
Active, not recruiting
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)
2023-506183-13-00· Phase 2· F. Hoffmann-La Roche AG· Source
Active, not recruiting
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473· Phase 3· Sanofi· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
2024-511057-22-00· Phase 3· Janssen Cilag International· Source
Completed
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source
Completed
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928· Phase 2· H. Lundbeck A/S· Source
Terminated
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
NCT06220669· Phase 2· Eli Lilly and Company· Source
Completed
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· Phase 3· AbbVie· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Completed
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study
2024-511560-93-00· Phase 3· Boehringer Ingelheim International GmbH· Source
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· Phase 3· Novo Nordisk A/S· Source
Completed
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT04408755· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source
Report an error